Blockbuster Cancer Treatment Stymied by Supply Chain—for Now

J&J Revamps Drug Research, Plots Medical Device Deals

Big Pharma’s Battle With the Biden Administration Could Have Legs

Kenvue Stock Falls 6%, Drops Below IPO Price

Healthcare Stocks Push the Dow Higher

Stock Market News

Cidara Shares Rally Premarket as J&J Moves Forward on Influenza Pact

J&J’s $40 Billion Split-Off Sets Stage for Pharma, Medical Tech Expansion 

As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs 

J&J Dividend Decision Shows Power of Free Cash Flow

Health Care Roundup: Market Talk

Johnson & Johnson Maintains Dividend After Kenvue Spinout

Johnson & Johnson Revises 2Q Results After Kenvue Split

Johnson & Johnson Adjusts Full-Year Outlook to Reflect Kenvue Split

Crypto Scores Big Win Over the SEC. Why the Battle’s Far From Over.

Johnson & Johnson 2Q Adj EPS $2.56 >JNJ

Kenvue Fits Right In With Other Dividend Aristocrats

Expensive Drugs Targeted for First U.S. Price Negotiations

The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List

First 10 Drugs Picked for Medicare Price Negotiations